Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Kala Pharmaceuticals (KALA) Reports In-Line Q2 EPS
August 6, 2020 8:55 AM EDTKala Pharmaceuticals (NASDAQ: KALA) reported Q2 EPS of ($0.41), in-line with the analyst estimate of ($0.41).
We are very pleased with our progress in the second quarter, said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. In May, the FDA accepted our NDA... More
